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Puberty and menstruation are difficult issues for teens with disabilities and for their families as
well. Irregular bleeding, mood swings, and problems with hygiene often complicate the delicate
balance in the lives of these adolescents. The care provider is asked to help with the pubertal
transition and the issues surrounding menstruation and reproductive health. This review will
concentrate on the issues concerning menstruation that need special focus in teens with develop-
mental disability (DD). The impact of the menstrual cycle on these teenagers, including hygiene
issues, menstrual irregularities due to specific clinical circumstances, and treatment dilemmas
associated with the use of hormonal medication will be discussed for this special group of teens.
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Introduction
Pubertal development and the subsequent onset of
menses are the beginning of a significant change for
many adolescents. This may even be more for a teen
with developmental disability (DD), for whom life it-
self is challenging, and mental and physical health is
often in a delicate balance. The changes attendant on
puberty can cause this balance to shift significantly.
The care provider for these adolescents will be called
upon to help manage this transition time and guide
the teen and her family through this time by means of
education, understanding, and good medical care.
This review will concentrate on issues concerning
menstruation and reproduction, areas that need spe-
cial focus in teens with DD. Menstrual cycle problems
related to the disabilities, including clinical circum-
stances like medications and issues related to hygiene,
will be addressed. Treatment dilemmas associated with
the use of hormonal medications specific to teens with
disabilities will also be discussed. Data are sparse on
many issues, and research in women with develop-
mental disabilities is often retrospective because of
circumstances requiring informed consent. Many rec-
ommendations are therefore extrapolated from the lit-
erature on the general population.
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Issues Specific to the Menstrual Cycles
of Teens with DD
Epidemiology
Studies from the United States suggest a lowering in
the age of onset of puberty over the past 40 years of be-
tween 0.5 and 1.0 years, with black girls maturing 0.5 to
1 year earlier than white girls. There has been a smaller
decrease in the mean age at menarche on the order of
0.2 years.1 The most recent results from the NHANES
(National Health and Nutrition Examination Survey)
study suggest that the mean age of menarche declined
by 0.9 year overall in women born before 1920 com-
pared to women born in 1980–84; the declines in the
mean age at menarche ranged from 0.7 to 1.4 years,
depending on the race/ethnic group.2 There is little
information on the epidemiology of menstrual cycles
in women with developmental disabilities. One study
looking at 35 women with autism spectrum conditions
found an average delayed age of menarche by 8 months
(13 years and 4 months as opposed to 12 and 7 months
in a control group) They also found 4 girls with extreme
late onset of puberty (17–20 years).3 Looking at a large
group of children with cerebral palsy, puberty began
earlier, but ended later in white children with CP, com-
pared with white children in the general population.
In addition, menarche occurred at age 14 in white girls
with CP.4 FSH and LH responses to GnRH stimulation
in teenagers with and without developmental disabili-
ties showed an impaired response of the FSH-secreting
pituitary cells in initial pubertal stages. This difference
disappeared during further sexual development.5
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Although one study found that in women with Down
syndrome with regular cycles, ovulatory events were
less frequent and often characterized by luteal phase
defects,6 another study could not confirm that.7 Over-
all, there are no clear data to suggest that the onset of
menarche or the cycles of women with developmen-
tal disabilities are very different due to the disability,
except in some specific conditions, like autism. There
are, however, several other common factors that may
contribute to menstrual irregularities.
Common Factors That Contribute
to Menstrual Irregularities
in Women with DD
Women with epilepsy have an increased incidence of
reproductive endocrine disorders, including irregular
menstrual cycles, anovulatory cycles, amenorrhea. and
oligomenorrhea.8 Polycystic ovary syndrome occurs in
10–20 percent of women with epilepsy compared to
5–6 percent in the general population. Women on
valproic acid may have an even higher incidence of
up to 60%.9–11 Many anticonvulsants, including car-
bamazepine, felbamate, fenytoin and phenobarbitol,
increase the activity of the cytochrome P450 hepatic
micrososmal oxidative enzymes. This results in more
rapid clearance of steroid hormones and may lead
to menstrual irregularities. Antipsychotics and meto-
clopramide can cause hyperprolactinemia, which can
lead to abnormal bleeding and ultimately to amen-
orrhea due to hypoestrogenemia with concerns about
bone loss.12
Thyroid disease, which can lead to subsequent dis-
turbance of the cycle, is more prevalent in women with
Down syndrome.13 Teens with swallowing problems
or feeding tubes may have such a low weight that they
experience hypothalamic oligo- or amenorrhea.
Menstrual Hygiene
Issues surrounding menstrual hygiene are a com-
mon point of discussion with teens with DD and their
families.14 Once menarche occurs, girls with DD may
have physical challenges that may make menstrual hy-
giene difficult, or they may be unable to deal with
menstrual pads. The teen may remove the pads in in-
appropriate places on account of a heightened sensory
awareness of discomfort from the pads. Some teens
cannot physically change their own pads, which may
interfere with their ability to be independent; this may
be seen in teens with CP or spina bifida. Other girls
may have difficulty communicating about the men-
strual cycle. Problems may arise if caregivers at school
or at home are unable or unwilling to help with hy-
giene, so that the teens may end up staying home from
school. Some of these issues can be remedied with pa-
tient or caregiver education, focusing on the normalcy
of periods in all women, explaining that this is not
“painful or bad blood,” and providing help to the fam-
ily and school caregivers with the management of pads.
This education will include the adolescent (most teens
that are toilet-trained can be taught how to deal with
pads) and her family or the school caregivers, making
sure that all issues are addressed.
Amenorrhea
Although having no periods may appear to be a
good thing for the teen and her family, amenorrhea
may be an indication of anovulation, with its poten-
tial for endometrial hyperplasia if left untreated. Low
weight or hyperprolactinemia can cause low estrogen
levels and subsequent amenorrhea. Secondary amen-
orrhea during the years of adolescence may play a role
in the development of osteoporosis or osteopenia in
later years.15 A diagnosis for the cause of amenorrhea
needs to be made, and the issues discussed with the
patient and her family, so that an appropriate plan can
be devised.
Request for Birth Control: Assessment
of Sexuality and Education
The call for cessation or management of menses
may also be combined with an underlying request for
birth control. If the request comes from the teenager,
the clinician should plan to spend some private time
with her and try to assess whether she could consent
to a sexual relationship. The clinician should investi-
gate the adolescent’s level of sexual education. Simple
terms and repetition of topics should be used when
educating adolescents with special needs. Visual aids,
pictures, signs, symbols, and anatomically correct dolls
or models are very useful to assess knowledge and help
with understanding.
If the request for menstrual suppression comes from
the caregivers, assess the adolescent’s safety at home
and at school. Always address the risk for abuse, which
is thought to be increased in teens with disabilities.16
Cyclical Behavioral Changes
Cyclical behavioral changes are a common issue for
women with developmental disabilities (16%).17 The
cyclical behavior in women with DD may be very dif-
ferent from what is typically thought of as PMS in
adult women; it may include temper tantrums, cry-
ing spells, autistic behavior, self-abusive behavior, or
seizures. Menstrual calendars in combination with
symptom calendars are used to make the diagno-
sis of menstrual-related mood and behavioral symp-
toms, as well as to assess treatment success. The
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diagnostic criteria for PMS as described in the ACOG
Committee Opinion on PMS indicate that one of
the described symptoms in the affective and somatic
categories should be present in the 4 days prior to
menses and not reoccur until in the 12 days prior to the
next cycle in three consecutive cycles.18 For teens with
DD, help is usually needed to document symptoms:
parents and teachers need to keep daily records of the
most bothersome symptoms for 3 months. In that way,
true menstrual cyclicity can be documented and other
behavior patterns can be investigated. Dysmenorrhea
is very common in teenagers (10–45%),19 and teens
who cannot communicate their discomfort or pain may
manifest changes in behavior. Once cyclical behav-
iors are documented, non-steroidal anti-inflammatory
drugs (NSAIDs) should be the first-line treatment for
suspected dysmenorrhea; NSAIDs should be given
in appropriate doses starting on the first day of be-
havioral changes. This was found to be successful in
two-thirds of adult patients with DD.17 If that is un-
successful, menstrual manipulation can be attempted
with oral contraceptives or progestins. An oral contra-
ceptive with drospirenone may be helpful.20 Menstrual
suppression with depot medroxyprogesterone has also
been used, although data to support behavioral bene-
fits are sparse. Success of these treatments in women
with disabilities has not been well studied.
Selective serotonin reuptake inhibitors (SSRIs) have
been used extensively to manage severe PMS and
PMDD in the general population and have been found
to be very helpful.21 However, this class of medication
has not been studied for this indication in women with
DD. In view of recent warnings of suicides in teens on
certain SSRIs, as well as the possibility of interaction
with the many medications that teens with DD take,
caution and a consultation with a neurologist and/or
psychiatrist are recommended.
Diagnosis and Work-Up
If a teen with DD and her family come to dis-
cuss menstruation, the scope of the issues needs to
be determined. Is there truly abnormal bleeding, se-
vere dysmenorrhea or anemia, or is there a request for
hygiene or a concern about sexual activity or abuse?
Do the cycles affect the life of the teenager and her care-
givers negatively? A bleeding calendar may be helpful.
Irregular anovulatory bleeding due to the immature
hypothalamic-pituitary-ovarian axis is very common
during the first two post menarchal years and may
persist for up to 5 years.22 Reassurance is often all that
is needed. If the bleeding is excessive or leads to hospi-
talization, a thorough work-up is indicated, including
hemoglobin, thyroid function testing, prolactin screen-
ing, and a search for bleeding disorders.
Ultrasounds or pelvic exams are rarely indicated in
adolescents with DD and menstrual abnormalities, as
structural lesions as a cause for abnormal bleeding in
teens are unusual. The sexually active teen needs to be
screened appropriately by cytologic study of the cervix
and for STI per screening guidelines for all adoles-
cents.
Treatment
The decision to treat the patient’s menstruation is
based on an individual assessment of the menstrual cy-
cle, the tolerance of the patient of her periods and the
products used, as well as the impact of the cycles on
her daily activities. Routine requests for suppression of
puberty and menstruation without any particular iden-
tified problem should be resisted.23 Once the decision
is made to treat, treatment goals should be set with the
teen and her family. Goals could be to: decrease flow,
relieve pain or symptoms, provide contraception, or
obtain amenorrhea. Continued documentation of the
cycles by the family is very helpful to assess the efficacy
of treatment.
Before prescribing any hormonal treatment, a clini-
cian needs to realize that once interventions are started,
they are often continued indefinitely. Periodic evalua-
tion of continuation of treatment should be part of the
long-term goal.
The use of non-steroidal anti-inflammatory drugs
(NSAIDs) lessens dysmenorrhea and can decrease
menstrual flow by up to 20%.24 The dose needs to
be clearly prescribed, with adequate dosing inter-
vals, not on an as-needed basis. NSAIDs should be
used throughout the entire menstrual period. After 3
months, the effect of this course of treatment can be
assessed and if the desired outcome is not reached,
hormones are the next logical step.
Combined Contraceptives
If regularity or decrease in flow and cramping is
desired, low-dose combined contraceptives are a good
choice. Consistent pill intake is often an issue for adoles-
cents, and should be monitored closely by the parents
of girls with DD. If swallowing is difficult, the pill can be
taken with a favorite food; a chewable oral contracep-
tive is available, or a transdermal patch can be used.
Extended cycling is now widely used to achieve amen-
orrhea (up to 90% after the first few months) and early
studies show no concerns about safety.25 Troublesome
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spotting can be treated by taking two pills for several
days or taking periodic 4–7 day pill-free intervals to al-
low for a withdrawal bleed.26 Contraindications to es-
trogen/progestin combination oral contraceptives are
the same as in the general population, but there are
some specific concerns related to girls with DD. Deep
venous thrombosis (DVT) may be a concern, in the
context of decreased mobility for some girls with DD.
DVT is a disease with many risk factors, subdivided
into three groups: hypercoagulability, venous stasis, or
endothelial damage. There are few studies that ad-
dress this issue for women with DD. One small ret-
rospective study found that no DVT was recorded in
57 institutionalized residents during 18 years (but no
testing for asymptomatic DVT was performed).27 One
case report describes a tetraparesic woman on OCP
who sustained a DVT.28 Most of the studies on DVT
and immobilization have been related to air travel,
and suggest there may be other risk factors in this
situation, such as hyperbaric hypoxia.29 However, we
know that prolonged sitting does increase venous sta-
sis and hence theoretically the risk for DVT; it seems
prudent to be cautious with combined contraceptives.
Recommendations include using the lowest dose estro-
gen possible and avoiding third-generation progestins,
as they have been reported to increase the risk of DVT
twofold compared with second-generation OCPs.30 A
careful family history to assess for DVT/pulmonary
emboli is recommended31 and screening for the
common inherited thrombofilia factor V Leiden
should be considered if a positive family history is
obtained.
The transdermal patch can be used in women with
problems swallowing or forgetfulness, but the higher es-
trogen levels have been reported to be associated with a
twofold increase in DVT compared to a norgestimate-
containing oral contraceptive.32 The patch can cause
skin irritation in some. Occasionally girls with DD will
find the presence of the patch bothersome, and may
attempt to remove it. Placing the patch on the lower
part of the back may solve that problem.
The vaginal ring is usually not used in this
population because of issues concerning placement
and removal, which would need to be done by
caregivers.
Some preliminary data on the 20-mcg ethinyl estra-
diol pills suggest possible concern about bone mineral
density and bone accretion.33
Patients on enzyme-inducing antiepileptic drugs
(AEDs) may have decreased serum levels of estro-
gen and progestin, potentially leading to abnor-




If a teen has clearly anovulatory cycles, oral pro-
gestins like medroxyprogesterone, norethindrone, or
micronized progesterone, can be used for 10 days out
of the month. This complicated dosing regimen, and
the fact that it does not protect against pregnancy, make
it less desirable than oral contraceptives, but with good
supervision this can be used to regulate the cycles. If
amenorrhea is the goal, continuous oral progestins can
be used. Side effects include breakthrough bleeding or
mood disturbances, as well as an increased appetite
with megestrol acetate.
Depot Medroxyprogesterone Acetate
If complete cessation of menstruation is the goal,
depot medroxyprogesterone acetate (DMPA) 150 mg
given intramuscularly every 12 weeks (every 10 weeks
in women on enzyme-inducing AEDs) has been used
successfully, with amenorrhea rates approaching 70%
over time. Subcutaneous medroxyprogesterone acetate
has similar rates of amenorrhea (55% at 1 year).35 The
main concerns with DMPA are weight gain and its
impact on bone mineral density.
Both subcutaneous and intramuscular depot
medroxyprogesterone have been associated with
weight gain. This weight gain shows large variations
in several studies, but an average weight gain of 4.5
and 5.8 kg in three years was found in a comparison
study.36 Weight gain is of particular concern in this pa-
tient population, as the added body weight may make
mobility and transfers more difficult. Previous research
has shown a significant relationship between increased
body weight on DMPA and initial weight status, lead-
ing to higher gains in the already obese.37
Longitudinal studies have demonstrated consistent
loss in bone mass of 1–2% per year in DMPA users,
regardless of age. In adolescents, a 1–2% bone loss
with use of DMPA is dramatically different from the
increase in bone density (up to 9% annually) that is ex-
pected during adolescence without the use of DMPA.38
Therefore, use of DMPA in the adolescent may po-
tentially compromise adult peak bone mass, with the
potential for earlier osteoporosis and subsequent frac-
tures. There are now data suggesting that most bone
mass returns after stopping the injections.33 Whether
the fracture rate is affected has not yet been adequately
researched.39
Women with DD may have coexisting physical dis-
orders limiting mobility, which may affect bone density.
Significant decreases in bone mineral density scores
have been found in adults and children with physi-
cal disabilities.40,41 One large retrospective study using
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administrative data of 6,773 women and teens with
DD showed an increased fracture risk of 2.4 among
340 users of DMPA compared to nonusers, and a RR
for fractures of 1.9 among 1,909 users of AEDs.42 One
chart review in a primary care practice found more
reported fractures in adult women with DD then in
those without DD; these occurred at an average age
of 41.43
The issue of wheelchair use and the role that this
plays in bone mineral density has not been exten-
sively researched. One study from Europe suggested
decreased bone density in wheelchair-bound patients;
however, the sample studied was small.44 The impor-
tance of dietary intake or supplementation of vitamin
D and calcium needs to be emphasized, as an opti-
mal peak bone mass may not be reached if intake is
inadequate.
Implantable Progestin
The implantable progesterone rod, Implanon, has
not been studied in women with DD. Data suggest
an amenorrhea rate of 33%, but it causes significant
unscheduled bleeding, which may make it less desirable
in this population.45 Insertion may require sedation or
anesthesia and the implant is not recommended for
women on enzyme-inducing AEDs.
Levonorgestrel Intrauterine Device
The levonorgestrel-releasing intrauterine system
(LNG–IUS) causes a decrease in menstrual flow that
may become an alternative treatment for heavy cycles
in women with DD who have a normal uterine cavity.
This use of the device is off-label. With the LNG–IUS,
rates of amenorrhea are significant and side effects are
limited.46 In girls with DD, insertion may need to be
done under anesthesia, due to nulligravid status, un-
predictable cooperation, as well as the potential for
a small uterus. One study reported the insertion as
difficult in 14.9% of nulliparous women aged 18–25,
compared to 15.4% in a largely multiparous popula-
tion, and the IUD could not be placed in two cases
(2.1%).47
Surgical Alternatives
Usually hormonal treatment is adequate to address
menstrual issues in women with DD, but surgical mea-
sures, like endometrial ablation and hysterectomy may
be requested by the family, and need to be addressed.48
Both these measures would render the patient sterile,
which has ethical and legal implications.49 This is very
difficult decision, so in these rare circumstances, the
clinician should strongly consider consulting an ethics
committee and be aware of state laws.
Conclusion
The management of menstrual issues in adolescents
with developmental disabilities should be guided by
the same principles that apply to the general teen pop-
ulation. The medical careproviders should work with
the patients, parents, and caregivers to find an accept-
able course of action. Clinicians should always be con-
cerned about the vulnerability of this population. If the
cycles are limiting the patient’s ability to participate in
her regular activities and are clearly affecting her life,
treatment can be initiated with periodic evaluation of
the need for continuation. There is a paucity of data
on treatment options specific for women with DD. The
general concerns are outlined in this monograph, al-
though many recommendations are based primarily
on research in the general teen population.
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